Fig. 5: Reversal of the corticosterone-evoked persistent disruption of synaptic plasticity in anaesthetised transgenic rats by the inflammasome inhibitor Mcc950. | Neuropsychopharmacology

Fig. 5: Reversal of the corticosterone-evoked persistent disruption of synaptic plasticity in anaesthetised transgenic rats by the inflammasome inhibitor Mcc950.

From: Enduring glucocorticoid-evoked exacerbation of synaptic plasticity disruption in male rats modelling early Alzheimer’s disease amyloidosis

Fig. 5

A Schematic diagram of treatment regimen, starting at 5 months of age (online version in colour). B Whereas sHFS triggered robust LTP in wild-type rats pretreated 1 month previously with CORT (WT CORT 10), the same pretreatment in transgenic rats strongly inhibited LTP (TG CORT 10). Six-day i.p. treatment with Mcc950 (16 mg/kg/day) reversed the LTP deficit in transgenic rats (TG CORT 10 MCC950). An arrowhead indicates the time point of sHFS application. Inserts show representative EPSP traces at the times indicated. Calibration bars: Vertical, 1 mV, horizontal 10 ms. LTP magnitude was determined during the last 10 min. Statistical summary is in the right hand panel. Number of animals per group is shown on the bar. *p < 0.05 (one-way ANOVA followed by Bonferroni’s multiple comparison test); #p < 0. 05, ##p < 0.01 compared with pre-sHFS baseline (paired t test). Values are the mean ± S.E.M. % pre-HFS baseline EPSP amplitude.

Back to article page